Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...
In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...
Generic Victoza is a GLP-1 receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 ...
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...
The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), ...
The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes ...
The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...
Liraglutide injection is now approved for adult and pediatric patients ages 10 and up, proving another option amid the GLP-1 ...
The U.S. Food and Drug Administration (FDA) has approved a generic daily injectable for the GLP-1 medication for patients who ...
The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...
The ongoing shortage of liraglutide injection and other GLP-1 medications prompted the FDA to prioritize the generic drug applications for these medications in order to improve patient access.